Skip to main
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding Corp has received a positive response from the market, as evidenced by a ~4% increase in share price, indicating investor optimism regarding the company's prospects. The firm is perceived as undervalued, trading at approximately 14 times net cash, with a favorable risk/reward profile anticipated over the next 12 to 24 months. Moreover, recent Phase 3 SAPPHIRE data bolsters confidence in potential regulatory approval and commercial viability, with management successfully addressing prior concerns related to their CDMO facility, signaling readiness for advancements in drug production.

Bears say

Scholar Rock Holding Corp faces a negative outlook primarily due to the delayed commercial launch of its lead asset, apitegromab, which has been pushed back significantly from the previously anticipated timeline. This delay not only lowers the company's peak sales estimates for apitegromab to $1.7 billion by 2035 but also introduces increased regulatory, competitive, and pricing risks that could impact its market position. The issuance of a Complete Response Letter (CRL) indicates unresolved issues that need addressing before a resubmission to the FDA, thereby contributing to uncertainty in the company’s revenue projections moving forward.

SRRK has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 11 analysts, SRRK has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.